Next report date
≈
May 9
Report period
Q1 2025
EPS estimate
−0.15 USD
Revenue estimate
2.68 M USD
−1.31 USD
−24.77 M USD
0.00 USD
33.83 M
About Iterum Therapeutics plc
Sector
Industry
CEO
Corey N. Fishman
Website
Headquarters
Dublin
Founded
2015
ISIN
IE000TTOOBX0
FIGI
BBG00CL5KSM0
Iterum Therapeutics Plc operates as a pharmaceutical company, which engages in the development and commercialization of sulopenem. The company was founded by Corey N. Fishman on June 24, 2015 and is headquartered in Dublin, Ireland.
Q4 '23
Q1 '24
Q2 '24
Q3 '24
Q4 '24
−14.00 M
−10.50 M
−7.00 M
−3.50 M
0.00
Revenue
Net income
Net margin %
Revenue
COGS
Gross profit
Op expenses
Op income
Non-Op income/ expenses
Taxes & Other
Net income
−6.80 M
−5.10 M
−3.40 M
−1.70 M
0.00
Revenue
COGS
Gross profit
Expenses & adjustments
Net income
−6.80 M
−5.10 M
−3.40 M
−1.70 M
0.00
Q4 '23
Q1 '24
Q2 '24
Q3 '24
Q4 '24
−16.00 M
0.00
16.00 M
32.00 M
48.00 M
Debt
Free cash flow
Cash & equivalents
No news here
Looks like there's nothing to report right now
$ITRM idea **Not financial advice**
ITRM under $1 whilst being in NASDAQ, will need to reclaim the $1 before february. This will shoot up toward end of year whilst penny stocks are hot. looking to fill that $1.09 gap fill soon. Small amount of volume will send this. 15% risk at lows of 0.50 and potential profi
$ITRM can rise in the next daysContextual immersion trading strategy idea.
Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing anti-infectives for multi-drug resistant pathogens in Ireland and the United States.
The demand for shares of the company looks higher than the supply.
This and othe
See all ideas
Summarizing what the indicators are suggesting.
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of ITRM is 1.43 USD — it has decreased by −0.69% in the past 24 hours. Watch Iterum Therapeutics plc stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Iterum Therapeutics plc stocks are traded under the ticker ITRM.
ITRM stock has risen by 3.62% compared to the previous week, the month change is a −4.67% fall, over the last year Iterum Therapeutics plc has showed a −8.92% decrease.
ITRM reached its all-time high on Jun 8, 2018 with the price of 195.00 USD, and its all-time low was 0.60 USD and was reached on Dec 27, 2022. View more price dynamics on ITRM chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
ITRM stock is 9.49% volatile and has beta coefficient of 2.28. Track Iterum Therapeutics plc stock price on the chart and check out the list of the most volatile stocks — is Iterum Therapeutics plc there?
Today Iterum Therapeutics plc has the market capitalization of 49.80 M, it has increased by 8.21% over the last week.
Yes, you can track Iterum Therapeutics plc financials in yearly and quarterly reports right on TradingView.
Iterum Therapeutics plc is going to release the next earnings report on May 9, 2025. Keep track of upcoming events with our Earnings Calendar.
ITRM earnings for the last quarter are −0.12 USD per share, whereas the estimation was −0.17 USD resulting in a 29.41% surprise. The estimated earnings for the next quarter are −0.15 USD per share. See more details about Iterum Therapeutics plc earnings.
ITRM net income for the last quarter is −6.58 M USD, while the quarter before that showed −6.09 M USD of net income which accounts for −8.01% change. Track more Iterum Therapeutics plc financial stats to get the full picture.
No, ITRM doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Mar 25, 2025, the company has 9.00 employees. See our rating of the largest employees — is Iterum Therapeutics plc on this list?
Like other stocks, ITRM shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Iterum Therapeutics plc stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Iterum Therapeutics plc technincal analysis shows the neutral today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Iterum Therapeutics plc stock shows the sell signal. See more of Iterum Therapeutics plc technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.